# AstraZeneca vs Merck & Co: stocks compared

URL: https://funkfolio.com/compare/azn-vs-mrk

> AstraZeneca ($282.7B, P/E 26.0) and Merck & Co ($353.4B, P/E 145) compared: size, valuation, margins, debt, cash and price change.

---

## AstraZeneca vs Merck & Co

AstraZeneca (AZN), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Merck & Co is worth $353.4B on the stock market and AstraZeneca $282.7B: Merck & Co is valued at 25% more. AstraZeneca trades at 26.0 times earnings and Merck & Co at 145. Over the past year AstraZeneca's share price has moved +2.75% and Merck & Co's +49.8%.

### Key facts

- **AstraZeneca market value:** $282.7B
- **Merck & Co market value:** $353.4B
- **AstraZeneca P/E:** 26.0
- **Merck & Co P/E:** 145
- **AstraZeneca revenue:** $58.7B FY to 2025-12-31
- **Merck & Co revenue:** $65B FY to 2025-12-31
- **Superinvestors holding both:** 6

Market values as of 18 Nov 2026, 06:22 UTC.

AstraZeneca vs Merck & Co: every measure side by side

| Measure | AstraZeneca | Merck & Co |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United Kingdom | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $282.7B lower | $353.4B higher |
| Revenue | $58.7B lower | $65B higher |
| Earnings | $10.2B lower | $18.3B higher |
| Employees | 96,100 higher | 73,000 lower |
| Total assets | $114.1B lower | $136.9B higher |
| Valuation |  |  |
| P/E | 26.0 lower | 145 higher |
| P/S | 4.8 lower | 5.4 higher |
| P/B | — | 7.9 |
| Dividend yield | — | 2.33% |
| Profitability |  |  |
| Operating margin | 23.4% | — |
| Balance sheet |  |  |
| Net assets | $48.7B lower | $52.6B higher |
| Total liabilities | $65.4B lower | $84.2B higher |
| Total debt | $29.6B lower | $49.3B higher |
| Cash on hand | $5.7B lower | $14.6B higher |
| Price change |  |  |
| Today | -0.95% lower | -0.75% higher |
| 1 year | +2.75% lower | +49.8% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: AstraZeneca 101.9, Merck & Co 154.4.

- AstraZeneca (AZN)
- Merck & Co (MRK)

AstraZeneca and Merck & Co share prices over one year, rebased to 100: AstraZeneca ends at 101.9, Merck & Co at 154.4.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | AZN | MRK |
| --- | --- | --- |
| Nov 28, 2025 | 103.7 | 112.9 |
| Dec 31, 2025 | 102.8 | 113.4 |
| Jan 30, 2026 | 103.8 | 118.7 |
| Feb 27, 2026 | 116.6 | 133.3 |
| Mar 31, 2026 | 110.3 | 129.5 |
| Apr 30, 2026 | 104.8 | 117.6 |
| May 29, 2026 | 103.8 | 127.8 |
| Jun 30, 2026 | 106.1 | 138.4 |
| Jul 31, 2026 | 94.9 | 140.2 |
| Aug 31, 2026 | 90.7 | 159.1 |
| Sep 30, 2026 | 90.3 | 156.5 |
| Oct 30, 2026 | 104.4 | 161.0 |
| Nov 17, 2026 | 101.9 | 154.4 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (6)

- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 20.2% / 0.6%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 1.1% / 0.2%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.5% / 1.7%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.4% / 0.3%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / &lt;0.1%

#### AstraZeneca only (6)

- [Primecap team](https://funkfolio.com/gurus/primecap) 1.8%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 1.1%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.7%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.4%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) &lt;0.1%

#### Merck & Co only (17)

- [Bill Smead](https://funkfolio.com/gurus/bill-smead) 7.1%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 4.9%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) 2.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 2.0%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.6%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 1.5%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.4%
- [Prem Watsa](https://funkfolio.com/gurus/prem-watsa) 0.9%
- [Christopher Bloomstran](https://funkfolio.com/gurus/christopher-bloomstran) 0.6%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 0.5%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.4%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Merck & Co). [Who owns AZN](https://funkfolio.com/stock/AZN/superinvestors) · [Who owns MRK](https://funkfolio.com/stock/MRK/superinvestors)

### More on AstraZeneca

- [AstraZeneca (AZN) stock page](https://funkfolio.com/stock/AZN)
- [AstraZeneca market cap](https://funkfolio.com/stock/AZN/market-cap)
- [AstraZeneca revenue](https://funkfolio.com/stock/AZN/revenue)
- [AstraZeneca P/E ratio](https://funkfolio.com/stock/AZN/pe-ratio)
- [AstraZeneca operating margin](https://funkfolio.com/stock/AZN/operating-margin)
- [AstraZeneca total debt](https://funkfolio.com/stock/AZN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Merck & Co

- [Merck & Co (MRK) stock page](https://funkfolio.com/stock/MRK)
- [Merck & Co market cap](https://funkfolio.com/stock/MRK/market-cap)
- [Merck & Co revenue](https://funkfolio.com/stock/MRK/revenue)
- [Merck & Co P/E ratio](https://funkfolio.com/stock/MRK/pe-ratio)
- [Merck & Co operating margin](https://funkfolio.com/stock/MRK/operating-margin)
- [Merck & Co total debt](https://funkfolio.com/stock/MRK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### AstraZeneca against its closest peers

- [AstraZeneca vs Novartis](https://funkfolio.com/compare/azn-vs-nvs)
- [AstraZeneca vs UnitedHealth Group](https://funkfolio.com/compare/azn-vs-unh)
- [AstraZeneca vs Thermo Fisher Scientific](https://funkfolio.com/compare/azn-vs-tmo)

#### Merck & Co against its closest peers

- [Merck & Co vs UnitedHealth Group](https://funkfolio.com/compare/mrk-vs-unh)
- [Merck & Co vs Novartis](https://funkfolio.com/compare/mrk-vs-nvs)
- [Merck & Co vs AbbVie](https://funkfolio.com/compare/abbv-vs-mrk)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, AstraZeneca or Merck & Co?**

By market value, Merck & Co is the larger: $353.4B against $282.7B for AstraZeneca. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $58.7B for AstraZeneca.

**Which has the higher P/E ratio?**

Merck & Co: 145, against 26.0 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has more debt?**

Merck & Co: $49.3B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both AstraZeneca and Merck & Co?**

In their latest 13F filings, Sarah Ketterer, Brandon Haley, Ken Fisher, Temasek, Dodge & Cox team and Rajiv Jain hold both.

### Cite this page

Funkfolio, “AstraZeneca vs Merck & Co”, data as of 18 November 2026. https://funkfolio.com/compare/azn-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
